Derik De Bruin
Stock Analyst at B of A Securities
(4.67)
# 172
Out of 5,084 analysts
221
Total ratings
67.57%
Success rate
16.81%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies | Maintains: Neutral | $150 → $165 | $148.32 | +11.25% | 34 | Nov 25, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,260 → $1,390 | $1,422.81 | -2.31% | 11 | Sep 22, 2025 | |
| DHR Danaher | Maintains: Buy | $230 → $220 | $227.13 | -3.14% | 5 | Sep 22, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underperform | $19 → $27 | $40.71 | -33.68% | 5 | Aug 29, 2025 | |
| RVTY Revvity | Maintains: Buy | $116 → $110 | $102.55 | +7.26% | 3 | Jun 26, 2025 | |
| BRKR Bruker | Maintains: Buy | $61 → $50 | $48.22 | +3.69% | 13 | Jun 26, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $13 | $18.11 | -28.22% | 9 | Jun 26, 2025 | |
| QGEN Qiagen | Maintains: Buy | $50 → $53 | $47.08 | +12.57% | 6 | Jun 26, 2025 | |
| WAT Waters | Maintains: Neutral | $370 → $375 | $396.37 | -5.39% | 14 | Jun 26, 2025 | |
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $7.31 | +50.58% | 13 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $65 | $101.15 | -35.74% | 7 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $12.13 | +31.96% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $675 → $660 | $575.24 | +14.73% | 18 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $255 → $235 | $224.92 | +4.48% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $220 → $210 | $184.04 | +14.11% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $355 | $281.77 | +25.99% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $22.92 | +13.44% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $261.48 | +3.64% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $184.18 | -1.18% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $14.48 | +45.08% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $18.32 | +74.67% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $127.80 | -21.75% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $74.86 | +14.89% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $3.23 | +303.10% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $1.92 | +238.54% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $185.45 | +40.20% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $9.21 | +1,202.93% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $120.41 | -0.34% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $2.25 | +300.00% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $717.35 | -67.24% | 3 | Nov 2, 2018 |
Agilent Technologies
Nov 25, 2025
Maintains: Neutral
Price Target: $150 → $165
Current: $148.32
Upside: +11.25%
Mettler-Toledo International
Sep 22, 2025
Maintains: Neutral
Price Target: $1,260 → $1,390
Current: $1,422.81
Upside: -2.31%
Danaher
Sep 22, 2025
Maintains: Buy
Price Target: $230 → $220
Current: $227.13
Upside: -3.14%
Phibro Animal Health
Aug 29, 2025
Maintains: Underperform
Price Target: $19 → $27
Current: $40.71
Upside: -33.68%
Revvity
Jun 26, 2025
Maintains: Buy
Price Target: $116 → $110
Current: $102.55
Upside: +7.26%
Bruker
Jun 26, 2025
Maintains: Buy
Price Target: $61 → $50
Current: $48.22
Upside: +3.69%
10x Genomics
Jun 26, 2025
Maintains: Neutral
Price Target: $12 → $13
Current: $18.11
Upside: -28.22%
Qiagen
Jun 26, 2025
Maintains: Buy
Price Target: $50 → $53
Current: $47.08
Upside: +12.57%
Waters
Jun 26, 2025
Maintains: Neutral
Price Target: $370 → $375
Current: $396.37
Upside: -5.39%
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $7.31
Upside: +50.58%
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $101.15
Upside: -35.74%
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $12.13
Upside: +31.96%
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $575.24
Upside: +14.73%
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $224.92
Upside: +4.48%
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $184.04
Upside: +14.11%
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $281.77
Upside: +25.99%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $22.92
Upside: +13.44%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $261.48
Upside: +3.64%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $184.18
Upside: -1.18%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $14.48
Upside: +45.08%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $18.32
Upside: +74.67%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $127.80
Upside: -21.75%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $74.86
Upside: +14.89%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $3.23
Upside: +303.10%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $1.92
Upside: +238.54%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $185.45
Upside: +40.20%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $9.21
Upside: +1,202.93%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $120.41
Upside: -0.34%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $2.25
Upside: +300.00%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $717.35
Upside: -67.24%